PT-141 Peptide: What Bremelanotide Is and What It Is Approved For

PT-141 is bremelanotide, and it is an approved drug. That makes it unusual among the compounds sold as research peptides — most have no approval anywhere. Bremelanotide has a label, a defined indication, phase 3 trials and a published safety programme.

It is also approved for a specific population that most people buying it are not in.

The approval

How it works

Bremelanotide is an analogue of alpha-MSH and activates melanocortin receptors, principally MC4R in the central nervous system. That mechanism is genuinely different from the other class of drug used for sexual dysfunction.

This is why PT-141 attracted interest beyond its indication. A centrally acting compound targeting desire is a different proposition from a peripheral vasodilator, and no approved drug fills that role for men.

What the trials found

The RECONNECT programme comprised the phase 3 studies supporting approval, with prespecified and integrated subgroup analyses published subsequently. A separate publication reported the safety profile across the full clinical development programme.

• Effects were statistically significant on the trial’s desire and distress measures.

• Effect sizes were modest. This is characteristic of the HSDD treatment area generally, not specific to bremelanotide.

• Nausea was the dominant adverse effect, and the most common reason for discontinuation.

• Flushing and headache were also frequent.

• Transient blood pressure increase and heart rate decrease were observed after dosing — the basis of its cardiovascular cautions.

The melanocortin family

PT-141 sits in a family where receptor selectivity determines the effect, and its relatives illustrate why that matters.

Melanotan II is the cautionary relative. Its broad receptor activity produces pigmentation effects alongside the others, and it has been the subject of FDA warnings. Bremelanotide is more selective, which is part of why one is approved and the other is not. See the melanotan 2 guide.

Research-market PT-141 versus Vyleesi

Buying PT-141 as a research compound means buying an unapproved version of an approved drug. That is a different legal and practical situation from an entirely unapproved peptide — the safety information exists, it simply does not come with the vial.

See the PT-141 dosage guide for quantities, the FDA-approved peptides list for the wider approval picture, and the COA reading guide for verification.